Literature DB >> 16714955

An analysis of pediatric blood cultures in the postpneumococcal conjugate vaccine era in a community hospital emergency department.

Brian Sard1, Mary Christine Bailey, Robert Vinci.   

Abstract

OBJECTIVE: Blood cultures are commonly included in the evaluation of febrile children younger than 3 years without focal source of infection. Clinicians treat patients with a positive blood culture before final identification of the organism. Their treatment might include reevaluation in the emergency department (ED), additional tests, parenteral antibiotics, and hospital admission even for children who ultimately have false-positive (FP) blood cultures. The advent of pneumococcal conjugate vaccine (PCV) has made occult bacteremia less common, decreasing the likelihood that a positive blood culture result before final organism identification will be a true pathogen. This study will identify the characteristics of patients with FP blood cultures in the post-PCV era.
METHODS: Charts were reviewed of all children ages 1 to 36 months with a temperature of at least 38.08 degrees C who had a blood culture obtained in our community hospital ED from January 1997 to January 2005.
RESULTS: Bacteria grew in 106 (3.5%) out of 2971 blood cultures. True positives (TPs), defined as true pathogens, had a prevalence of 0.7%, representing 19.8% of positives. FPs, defined as contaminants, occurred in 2.8% of cultures, representing 80.2% of positives. Patients with FP cultures had lower mean white blood cell (WBC) counts (10.51 x 10(9)/L vs. 16.95 x 10(9)/L; P = 0.0001) and lower mean presenting temperatures (38.8 degrees C vs. 39.4 degrees C; P = 0.005). FPs had longer time to positivity (34.6 vs. 17.7 hours; P = 0.001) than TPs. A culture with a Gram stain suggestive of a contaminant, time to positivity greater than 24 hours and a WBC of less than 15 x 10(9)/L had a PPV for an FP of 97%. When analysis was restricted to well-appearing children age 2 to 36 months with temperature of more than 39 degrees C without focal source of infection who were discharged from the ED, these three criteria had a PPV for an FP of 100%. In these highly febrile children, the FPs had significantly lower WBCs (9.14 x 10(9)/L vs. 22.84 x 10(9)/L; P = 0.0001) and longer time topositivity (33.4 vs. 19.8 hours; P = 0.007) than TPs. The likelihood of obtaining FP cultures increased after the introduction of PCV from 62.5% to 87.8% odds ratio, 4.3; 95%confidence internal, 1.44-13.38).
CONCLUSIONS: In the post-PCV era, the majority of blood culture results will be FPs. FP cultures are predictable in febrile children with WBC counts less than 15.00 x 10(9)/L, time to positivity of more than 24 hours, and a Gram stain result suggestive of a contaminant. Prospective studies applying these criteria to the at-risk population for occult bacteremia are indicated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16714955     DOI: 10.1097/01.pec.0000215137.51909.16

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  19 in total

1.  Occult bacteremia etiology following the introduction of 13-valent pneumococcal conjugate vaccine: a multicenter study in Spain.

Authors:  Susanna Hernández-Bou; Borja Gómez; Santiago Mintegi; Juan J García-García
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-07       Impact factor: 3.267

2.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

Review 3.  Management of the non-toxic-appearing acutely febrile child: a 21st century approach.

Authors:  Ravi Jhaveri; Carrie L Byington; Jerome O Klein; Eugene D Shapiro
Journal:  J Pediatr       Date:  2011-05-17       Impact factor: 4.406

4.  Endocarditis with ruptured sinus of Valsalva aneurysm caused by nonvaccine Streptococcus pneumoniae serotype 21.

Authors:  Kamakshya P Patra; John A Vanchiere; Joseph A Bocchini; Amy C Wu; Robert D Jackson; Ernest A Kiel; Dennis Mello
Journal:  Tex Heart Inst J       Date:  2012

5.  Blood cultures in the emergency department evaluation of childhood pneumonia.

Authors:  Samir S Shah; Maria H Dugan; Louis M Bell; Robert W Grundmeier; Todd A Florin; Elizabeth M Hines; Joshua P Metlay
Journal:  Pediatr Infect Dis J       Date:  2011-06       Impact factor: 2.129

6.  RNA transcriptional biosignature analysis for identifying febrile infants with serious bacterial infections in the emergency department: a feasibility study.

Authors:  Prashant Mahajan; Nathan Kuppermann; Nicolas Suarez; Asuncion Mejias; Charlie Casper; J Michael Dean; Octavio Ramilo
Journal:  Pediatr Emerg Care       Date:  2015-01       Impact factor: 1.454

7.  Outcomes of febrile events in pediatric patients with sickle cell anemia.

Authors:  Krishnaveni Sirigaddi; Inmaculada Aban; Amelia Jantz; Brandi M Pernell; Lee M Hilliard; Smita Bhatia; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-01       Impact factor: 3.167

8.  Toward early identification of acute lung injury in the emergency department.

Authors:  Robert J Freishtat; Bahar Mojgani; David J Mathison; James M Chamberlain
Journal:  J Investig Med       Date:  2007-12       Impact factor: 2.895

9.  Should all children admitted with community acquired pneumonia have blood cultures taken?

Authors:  Eng Meng Lai; Anna Marie Nathan; Jessie A de Bruyne; Lee Lee Chan
Journal:  Indian J Pediatr       Date:  2014-09-03       Impact factor: 1.967

10.  Secular trends in pediatric bloodstream infections over a 20-year period at a tertiary care hospital in Germany.

Authors:  Markus Hufnagel; Anita Burger; Susanne Bartelt; Philipp Henneke; Reinhard Berner
Journal:  Eur J Pediatr       Date:  2008-01-30       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.